Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Sino Biopharmaceutical (SBMFF) Consolidated Net Income/Loss data is not available for the most recently reported fiscal quarter, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Consolidated Net Income/Loss |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$3.48B |
|
$1.11B |
|
$5.73B |
|
$9.21B |
|
$3.03B |
|
$139.48M |
|
$363.60M |
|
$3.39B |
|
$5.82B |
|
$5.39B |
|
$5.82B |
|
18.79B |
|
| Cash Flow Statement Financials | |
$425.14M |
|
$-281.85M |
|
$-566.14M |
|
$1.04B |
|
$617.23M |
|
$-419.22M |
|
-- |
|
$-122.80M |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|